Bone-marrow-derived multipotent progenitor stromal cells — or mesenchymal stem cells (MSCs) — are the common predecessors of cells of the mesenchymal lineage, such as bone, cartilage and fat ...

It’s an essential in my cold-weather skin care routine.

Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (GVHD) finally reached the FDA green light.

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Food and Drug Administration (FDA) approved the first mesenchymal stromal cell (MSC) therapy, RYONCIL®, indicated for steroid-refractory acute graft ...

Fresh from its landmark US regulatory approval for its stem-cell product for paediatric graft-versus-host disease (GvHD), ...

Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Mesoblast (MESO) to $24 from $15 and keeps an Overweight rating on the ...

The homegrown therapy is the first mesenchymal stromal cell treatment that has gained the greenlight on the Chinese mainland. The approval was issued through an accelerated market registration ...

ASX investors are sending the Mesoblast Ltd (ASX: MSB) share price soaring again today. Here’s what’s spurring investor ...

Preliminary work by Farmer and Wang proved that prenatal surgery combined with human placenta-derived mesenchymal stromal cells, held in place with a biomaterial scaffold to form a “patch ...